Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: allopurinol Clear all
Recruiting Phase 2 Interventional

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT05536349
View directory record Official record
Conditions
Leukemia
Interventions
Pirtobrutinib, Obinutuzumab, Venetoclax, Valacyclovir, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 29, 2026, 3:23 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 29, 2026, 3:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

NCT04746989
View directory record Official record
Conditions
Gout
Interventions
Probenecid, Allopurinol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
294,878 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

NCT01407874
View directory record Official record
Conditions
Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency
Interventions
Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 29, 2026, 3:23 PM EDT
Completed No phase listed Observational

Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information

NCT04853160
View directory record Official record
Conditions
Gout, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
21 Years and older
Enrollment
24,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178
View directory record Official record
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

NCT01101035
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Febuxostat, Allopurinol
Drug
Lead sponsor
Takeda
Industry
Eligibility
50 Years and older
Enrollment
6,198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
202
States / cities
Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 29, 2026, 3:23 PM EDT
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Center of Research Translation (CORT) Project 2

NCT02038179
View directory record Official record
Conditions
Pre-hypertension, JNC 7 Stage I Hypertension
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131
View directory record Official record
Conditions
Gout
Interventions
Lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Pinson, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 29, 2026, 3:23 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

NCT04026776
View directory record Official record
Conditions
Salt; Excess, Blood Pressure Disorders
Interventions
Allopurinol, Dietary Intervention
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Years to 33 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

NCT00053196
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, G-CSF, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic cell transplantation, allopurinol
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
12
States / cities
La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2Phase 3 Interventional

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
View directory record Official record
Conditions
Gout
Interventions
ABP-671, Allopurinol, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
19 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

NCT04327024
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Granada Hills, California • Northridge, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Antioxidants on Skin Blood Flow-BH4

NCT03680573
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control: Lacated Ringers, Apocynin, Allopurinol, BH4, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Acetyl-ß-methylcholine chloride
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 29, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional Results available

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

NCT00899431
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Fludarabine, Rituximab, Thymoglobulin, Stem Cell Transplantation, Bendamustine, Allopurinol
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Phentermine/Topiramate for Uric Acid Stones

NCT04621929
View directory record Official record
Conditions
Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions
Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

NCT05665699
View directory record Official record
Conditions
Gout
Interventions
D-0120, Allopurinol
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Plantation, Florida • Evergreen Park, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

NCT02046694
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Allopurinol
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 30 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
165
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 29, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 29, 2026, 3:23 PM EDT
Completed No phase listed Observational

PERL Continuous Glucose Monitoring (CGM) Study

NCT03334318
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Mean blood glucose, Blood glucose CV, % time 70-180 mg/dL, % time below 54 mg/dL, % time above 180 mg/dL, % time above 250 mg/dL, MAGE (Mean amplitude of glucose excursions), LBGI (Low Blood Glucose Index), HBGI (High Blood Glucose Index), Allopurinol, Placebo
Other · Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 29, 2026, 3:23 PM EDT